Compare PED & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PED | IFRX |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 60.6M |
| IPO Year | 2012 | 2017 |
| Metric | PED | IFRX |
|---|---|---|
| Price | $16.47 | $0.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $30.00 | $8.50 |
| AVG Volume (30 Days) | ★ 827.2K | 187.2K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,553,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $305.89 | $1,054.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 28.49 | N/A |
| 52 Week Low | $0.43 | $0.71 |
| 52 Week High | $18.89 | $1.94 |
| Indicator | PED | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 88.65 | 49.69 |
| Support Level | $0.54 | $0.75 |
| Resistance Level | N/A | $1.16 |
| Average True Range (ATR) | 0.47 | 0.07 |
| MACD | 1.64 | 0.01 |
| Stochastic Oscillator | 85.71 | 38.89 |
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.